Abstract
Introduction/BackgroundPARP (poly adenosine diphosphate [ADP]-ribose polymerase) inhibitors are approved as maintenance therapy in platinum sensitive ovarian cancer (OC), in first line and in the recurrent setting, regardless of BRCA mutational...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have